

Eri T Kato

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/710389/publications.pdf>

Version: 2024-02-01

24
papers

8,934
citations

623734
14
h-index

713466
21
g-index

24
all docs

24
docs citations

24
times ranked

8812
citing authors

#	ARTICLE	IF	CITATIONS
1	Ischemic and Bleeding Events After First Major Bleeding Event in Patients Undergoing Coronary Stent Implantation. American Journal of Cardiology, 2022, 162, 13-23.	1.6	1
2	Modifiers of the Risk of Diabetes for Long-Term Outcomes After Coronary Revascularization. JACC Asia, 2022, , .	1.5	0
3	Antihyperglycemic therapies and cardiovascular outcomes in patients with type 2 diabetes mellitus: State of the art and future directions. Trends in Cardiovascular Medicine, 2021, 31, 101-108.	4.9	5
4	The efficacy and safety of dapagliflozin in women and men with type 2 diabetes mellitus. Diabetologia, 2021, 64, 1226-1234.	6.3	15
5	Sodium-glucose Co-transporters-2 Inhibitors and Heart Failure: State of the Art Review and Future Potentials. International Journal of Heart Failure, 2020, 2, 12.	2.7	15
6	Direct comparison of optical coherence tomography and high-definition 60-MHz intravascular ultrasound imaging of intra-procedural stent thrombosis in a patient with acute coronary syndrome. Cardiovascular Revascularization Medicine, 2019, 20, 365-367.	0.8	5
7	Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLAREâ€™TIMI 58 randomised trial. Lancet Diabetes and Endocrinology,the, 2019, 7, 606-617.	11.4	482
8	Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus. Circulation, 2019, 139, 2528-2536.	1.6	415
9	Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus. Circulation, 2019, 139, 2022-2031.	1.6	523
10	Response by Kato et al to Letter Regarding Article, â€œEffect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitusâ€. Circulation, 2019, 140, e740-e741.	1.6	6
11	Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. New England Journal of Medicine, 2019, 380, 347-357.	27.0	4,159
12	SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet, The, 2019, 393, 31-39.	13.7	1,958
13	Overview of oral antithrombotic treatment in elderly patients with atrial fibrillation. Ageing Research Reviews, 2019, 49, 115-124.	10.9	34
14	The design and rationale for the Dapagliflozin Effect on Cardiovascular Events (DECLARE)â€™TIMI 58 Trial. American Heart Journal, 2018, 200, 83-89.	2.7	117
15	<scp>DECLAREâ€™TIMI</scp> 58: Participantsâ€™ baseline characteristics. Diabetes, Obesity and Metabolism, 2018, 20, 1102-1110.	4.4	96
16	Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease. New England Journal of Medicine, 2017, 377, 1217-1227.	27.0	780
17	Efficacy and Safety of Adding Ezetimibe to Statin Therapy Among Women and Men: Insight From IMPROVEâ€™IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Journal of the American Heart Association, 2017, 6, .	3.7	43
18	A method and preliminary results of <i>in silico</i> computer simulation for the formation of mix thrombi with platelet and fibrin. Journal of Biorheology, 2017, 31, 30-34.	0.5	4

#	ARTICLE	IF	CITATIONS
19	Efficacy and Safety of Edoxaban in Elderly Patients With Atrial Fibrillation in the ENGAGE AFâ€TIMI 48 Trial. Journal of the American Heart Association, 2016, 5, .	3.7	215
20	The effect of rivaroxaban on myocardial infarction in the ATLAS ACS 2 - TIMI 51 trial. European Heart Journal: Acute Cardiovascular Care, 2015, 4, 468-474.	1.0	18
21	Intravascular ultrasound-guided percutaneous coronary interventions with minimum contrast volume for prevention of the radiocontrast-induced nephropathy: report of two cases. Cardiovascular Intervention and Therapeutics, 2011, 26, 83-88.	2.3	16
22	Potential difficulty for accurate categorization of drug-eluting stent thrombosis without coronary angiography: unignorable involvement of the cases with new onset acute myocardial infarction occurred in target vessels. Cardiovascular Intervention and Therapeutics, 2011, 26, 109-116.	2.3	0
23	A simple method preventing tangling of the guidewires during percutaneous coronary intervention for bifurcation lesions. Cardiovascular Intervention and Therapeutics, 2011, 26, 117-123.	2.3	0
24	Important Regulatory Role of Activated Platelet-Derived Procoagulant Activity in the Propagation of Thrombi Formed Under Arterial Blood Flow Conditions. Circulation Journal, 2009, 73, 540-548.	1.6	27